newsfilter
← Latest News
GlobeNewswire·

Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

SIG-002, Sigilon's lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of 2023 Pipeline prioritization extends anticipated cash runway into 2025 CAMBRIDGE,